DUPIXENT®

Dosing

DUPIXENT offers the choice of at‑home or in‑clinic administration

Recommended dosing for adult patients with inadequately controlled severe CRSwNP¹

Designed with patients in mind. DUPIXENT has 2 self-administration options^1,2

DUPIXENT is intended for use under the guidance of a healthcare professional. A patient may self-inject DUPIXENT after training in subcutaneous injection technique using the pre-filled syringe or the pre‑filled pen. Provide proper training to patients and/or caregivers on the preparation and administration of DUPIXENT prior to use according to the Instructions for Use.¹

DUPIXENT can be administered in the practice under the guidance of a healthcare professional if the patient is not an appropriate candidate for self-administration.¹

DUPIXENT is sterile and preservative-free. Discard any unused portion. Store refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. If necessary, DUPIXENT may be kept at room temperature up to 25°C (77°F) for a maximum of 14 days. Do not store above 25°C (77°F). After removal from the refrigerator, DUPIXENT must be used within 14 days or discarded. Do not expose DUPIXENT to heat or direct sunlight. Do NOT freeze. Do NOT shake.¹

^a300 mg/2 mL solution.

ABBREVIATION
CRSwNP, chronic rhinosinusitis with nasal polyps

REFERENCES

1. DUPIXENT (dupilumab). Summary of Product Characteristics. (UK).
2. Dupixent Patient Information Leaflet. (UK).